In acute myeloid leukemia (AML) cells, HDAC inhibitors induce drug resistance via hyperacetylation of histone proteins in the promoter regions of MDR1, BCRP, and MRP8 [24], indicating that HIF-1α acetylation may also regulate the effects of anticancer therapeutics. The gene discussed is H2BC12L; the disease is acute myeloid leukemia.